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Abstract
Background: It has been observed that patients with liver dysfunction need lower dose anesthetic compared
patients with normal liver function. The minimum amount of volatile anesthetic to achieve an optimal depth of
anesthesia for these patients is still unclear. In this study, Minimum alveolar concentration (MAC) of the sevoflurane
was determined using an electric stimulation and the effect of severity of liver dysfunction on the MAC was
observed in cirrhotic patients.
Methods: Thirty patients undergoing upper abdominal surgery were divided into the following groups: group
N (normal liver function), group A (Child-Pugh grade A) and group B (Child-Pugh grade B-C). Neuropsychological tests
were performed before surgery. We measured MACelectric (minimum alveolar concentration that prevents movement in
response to an electric stimulation in 50 % of patients) of sevoflurane in cirrhotic patients with liver dysfunction using
an electrical stimulation of 80 mA at 50 Hz, and analyzed factors that associated change of MAC.
Results: According to the neuropsychological tests, there were 7 and 4 patients with minimal hepatic encephalopathy
in Groups B and A, respectively. MACelectric in cirrhotic patients with liver dysfunction decreased significantly compared
to that in healthy liver patients (1.51 ± 0.16 vol. %, 1.33 ± 0.14 vol. % and 1.17 ± 0.13 vol. % in Group N, A and B,
respectively), while MACelectric was comparable between the cirrhotic patients with different Child-Pugh grade.
The Alanine Aminotransferase (ALT) and baseline values of bispectral index (BIS) were risk factors associated with
the lowering of MACelectric (p < 0.05).
Conclusion: MACelectric of sevoflurane in cirrhotic patients was significantly lower than that of patients with a
healthy liver. The severity of liver dysfunction had no effect on the MACelectric of sevoflurane in cirrhotic patients.
Trial registration: This study has been registered in the Chinese Clinical Trial Register in August 3, 2011 (No.
ChiCTR-TRC-11001507).
Keywords: Sevoflurane, Minimum alveolar concentration, Bispectral index, Liver cirrhosis, Minimal hepatic
encephalopathy
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Background
The minimum alveolar concentration (MAC) of anesthetic
that prevents movement in 50 % of subjects in response to
a noxious stimulus [1], is used to measure the capability of
volatile anesthetics to immobilize patients who are exposed
to noxious stimulation. However, it has been shown that
MAC may be affected by many pathophysiological condi-
tions and disease states in animals and patients [2–7]. The
liver is a vital organ involved in drug distribution,
metabolism, and elimination. Although the lifespan of
people with asymptomatic liver cirrhosis is not differ-
ent from that of healthy people [8], the perioperative
morbidity and mortality increase significantly in pa-
tients with liver cirrhosis [9, 10].
It has been shown that there is an association between
excessive depth of anesthesia and poor postoperative out-
comes, especially in high-risk patients [11, 12]. Providing
safe and effective anesthesia in patients with cirrhosis and
liver dysfunction has been a daunting challenge for most
of the anesthesiologists. Various clinical and animal stud-
ies suggest that volatile anesthetic requirement is de-
creased in subjects with liver dysfunction and is correlated
with the severity of liver dysfunction [13–15]. However, to
our knowledge, the MAC to a noxious stimulus of a vola-
tile anesthetic has not been previously evaluated in cir-
rhotic patients. Thus, we aimed to determine the MAC
values (MACelectric) of sevoflurane in cirrhotic patients by
using a supramaximal electric stimulation and evaluate
the effect of severity of liver dysfunction on MACelectric.
We provided data that shed light on the impact of
liver dysfunction on the requirement of volatile anes-
thetics in humans.
Methods
The research protocol was approved by the Institu-
tional Review Board (IRB) of West China Hospital.
Patients undergoing selective upper abdominal surgery
from September 2012 to June 2013 were screened for
this study. Excluded from enrollment were patients with:
1) difficult airway; 2) illiteracy who could not follow
instructions; 3) a body mass index (BMI) ≥30 kg/m2;4)
taking chronic sedatives and alcoholics; and 5) serious dis-
eases other than liver diseases, such as cardiovascular, re-
spiratory, endocrine system conditions. For those who
met the inclusion criteria and were willing to participate,
written informed consent was obtained from each patient.
A total 30 male patients were enrolled and divided into
three groups according to their liver function status:
Group N, patients with normal liver function undergoing
upper abdominal surgery (n = 10); Group A, patients with
cirrhotic liver of Child-Pugh grade [16] A (score 5 or 6)
undergoing hepatectomy (n = 10); Group B, patients
cirrhotic liver of Child-Pugh grade B or C (score ≥ 7)
undergoing Minch devascularization and splenectomy
or liver transplantation (n = 10). Diagnosis of cirrhosis
was based on clinical, biochemical, ultrasonographyor
computed tomography scan and liver histological
findings if available.
All patients were screened for minimal hepatic en-
cephalopathy (MHE) according to the Number Connec-
tion Test A (NCT-A) and Digit Symbol Test (DST) 1
day before the surgery. A test was considered abnormal
when the score was beyond ±2 SD from the score in the
age and education-matched control group [17, 18]. MHE
was diagnosed if one or two tests were abnormal.
All patients received an identical anesthetic technique
and monitoring devices, consisting of continuous electro-
cardiography, pulse oximetry, the arterial line for blood
pressure monitoring, nasopharyngeal temperature and
bispectral index (BIS) (BeneView T8, Cayman Mindray
Medical Electronics Co., Ltd, Shenzhen, China). Expired
sevoflurane and CO2 concentrations (ETCO2) were con-
tinuously monitored using infrared analyzers (M1026B,
Philips Medizin System Boeblingen GmbH, Boblingen,
Germany). None of the patients received premedication.
Anesthesia was induced using a mask with 8 % sevoflur-
ane in 6 L/min oxygen, and a Proseal laryngeal mask was
inserted when patients’ eyelash reflex was lost, and the
end-tidal sevoflurane was greater than 3 %. The oxygen
flow rate was then adjusted to 3 L/min, and normocapnia
(ETCO2 35–45 mmHg) was maintained. Manual ventila-
tion was administrated if necessary.
The MACelectric values were estimated using the
method previously described [19, 20]. An electrical
stimulation of 80 mA at 50 Hz (Neurostim T4, HSE,
Germany) on the ulnar aspect of the forearm at the mid-
point was performed for 15 s or until a purposeful
movement was observed [21]. Purposeful movement was
defined as a substantial movement of the head or ex-
tremities following the electric stimulation. Local muscle
contractions at the stimulation site and related finger
flexion constitute slight movement and are not regarded
as purposeful movement. The end-tidal sevoflurane con-
centration of the first patient in Group N began
from1.71 vol. % (MAC that produces immobility ex-
posed to a skin incision) [4]. When patients exhibited
purposeful movement, the end-tidal concentration of
sevoflurane was increased by 0.2 %, and the subjects
were retested after 10 min of re-equilibration. If the pa-
tient did not move, the end-tidal concentration of sevo-
flurane was decreased by 0.2 %. The MACelectric of each
patient was calculated as the value halfway between the
end-tidal concentrations that prevented or allowed
purposeful movement in response to the electrical
stimulation. The next patient’s initially end-tidal sevo-
flurane concentration was set at the MACelectric ob-
tained from the preceding patient. The same method
was used to determine the MACelectric for each
Yin et al. BMC Anesthesiology  (2016) 16:98 Page 2 of 7
patient’s. The MACelectric for each group was calcu-
lated as the mean of the ten patients.
Supramaximal stimulation is required to determine
MAC. Since previous studies have shown that pain
threshold increases in patients with liver dysfunction, we
used parameters that were determined by our pilot data
that showed the electric pain tolerance threshold were
41.9 ± 15.4, 50.5 ± 10.39 and 58.9 ± 2.08 mA in healthy,
Child grade A, and Child grade B patients (n = 10) re-
spectively. Initially, we used 60 mA as the highest
current to measure pain thresholds in the awaken pa-
tients and pain tolerance over 60 mA was recorded as
60 mA. In such cases, 60 mA was no longer supramaxi-
mal stimulation. Since 80 mA at 50 Hz has been con-
firmed to cause no damage to tissues in animals and
healthy volunteers, we chose to use 80 mA, instead of
60 mA, to determine MAC in this study.
All data were analyzed using the IBM SPSS Version
21.0. All original data were first analyzed with Shapiro-
Wilk test to examine whether data were in normal distrac-
tion. Data were presented as mean ± standard deviation
(SD). The data without normal distribution were pre-
sented as medians with maximum and minimum.
The results of the three groups were compared using
one-way ANOVA. Bonferroni or Dunnett T3 tests were
used to analyze the statistical difference between two
groups, according to the results of homogeneity test of
variance. Student’s t-test was used to compare the data
between patents with or without MHE. The Wilcoxon’s
signed rank test was used for data in non-normal distri-
bution. Related factors were analyzed using Spearman
correlation analysis and multiple linear regressions with
a stepwise selection method. p < 0.05 was considered sta-
tistically significant.
Results
All patients completed the study. The demographic data
of patients are reported in Table 1. The results of labora-
tory examination and the blood gas analysis are shown
in Tables 2 and 3 respectively. Compared to patients
with normal liver functions, the values of hepatic func-
tion and blood coagulation parameters were significantly
abnormal in patients with cirrhotic livers.
Results of neuropsychological tests and BIS values be-
fore the study are showed in Table 4. These values were
used to screen for MHE. Patients with Child-Pugh score
over 6 required longer time to finish NCT-A and achieved
lower DST scores compared to patients with healthy liver
(p < 0.05). Based on the results of NCT-A and DST, there
were 4 and 7 patients with MHE in Groups A and B, re-
spectively. The BIS values of Groups A and B were signifi-
cantly lower than those of Groups N. The BIS values in
cirrhotic patients with MHE were significantly lower than
those in patients without MHE (92.71 ± 3.82 vs. 95.88 ±
1.19, p = 0.025), when patients were awake.
The vital sign and BIS values measured continuously
during the study, which showed in Table 5. MAP, HR,
and SPO2 were kept stable throughout the study in three
groups, although MAP and HR significantly increased in
patients of Group A compared to patients of Group N
and B when performed the electric stimulation.
The results of MACelectric are presented in a box- and
-whisker plot (Fig. 1). The means of MACelectric in pa-
tients with liver dysfunction were significantly lower
than that of patients with normal liver functions (1.51 ±
0.16 vol. % for Group N, vs. 1.33 ± 0.14 vol. % or1.17 ±
0.13 vol. % for Group A and B, respectively, p < 0.05).
The difference between Groups A and B were not statis-
tically significant (p > 0.05). The mean MACelectric was
lower in patients with MHE compared with those with-
out it (1.19 ± 0.12 vol. % vs. 1.32 ± 0.14 vol. %, p = 0.028).
To examine the factors that may affect MACelectric,
Spearman analysis were used to analyze the correlation
between a number of factors and the change of MACelec-
tric. These factors were Child-Pugh score; NCT-A, DST,
BIS index, total bilirubin (TBIL), direct bilirubin (DBIL),
alanine aminotransferase (ALT), aspartame aminotrans-
ferase (AST), and albumin. Upon multivariate analysis,
ALT and BIS values before surgery were significantly
correlated with MACelectric among the groups. The re-
gression equation (MACelectric = −0.003 ALT +0.053 BIS)
was statistically significant (F = 3.845, p = 0.006).
Discussion
The end-tidal concentration of a volatile agent is an es-
sential component of the concept of MAC, which is
widely used as an index of anesthetic potency of a vola-
tile anesthetic. In this work, we found that the mean
MACelectric was significantly reduced in patients with
liver dysfunction (Child- Pugh grade A, and grade B or
C) compared to patients with normal liver function
(Group B vs. Group N, p < 0.001; Group A vs. Group N,
p < 0.05). This observation is consistent with published
Table 1 Demographic data
Group N Group A Group B P-value
Age (Years) 47.1 ± 10.73 47.9 ± 8.29 40.1 ± 8.39 0.133









Data were presented as the means and SDs
Abbreviations: BMI body mass index
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data [13–15]. We have previously reported that the sevo-
flurane MAC values in animals with chemically-induced
liver fibrosis were significantly lower than that in ani-
mals with normal liver function [14]. However, we did
not found statistically significant difference between pa-
tient groups with different levels of liver dysfunction
(Group A vs. Group B, p > 0.05). This is likely due to the
fact that the study was under powered and limited by
the relatively small sample size. Both Wang [13] and
Kang et al. [15] report that the severity of liver dysfunc-
tion influenced the requirements of volatile anesthetic in
orthotopic liver transplantation patients to maintain pre-
set anesthetic depths, as monitored by a target BIS. In
addition to sample size, other factors may also contrib-
ute to this discrepancy, such as patient characteristics
and use of different score systems for the severity of liver
diseases. Nonetheless, it is clear that liver dysfunction
status plays a significant role in the requirement of vola-
tile anesthetics.
The mechanisms of reduced volatile anesthetic re-
quirement in cirrhotic patients are poorly understood.
We demonstrate that ALT and BIS were the risk factors
associated the decrease of MACelectric. These results sup-
port the notion that these parameters may be used as
important predictors of decreased requirement of sevo-
flurane in these patients. Accumulating evidence sup-
ports that inhaled anesthetics exert their effects by
acting on ion channels and receptors in neurons and al-
tering synaptic transmission in the central nervous sys-
tem [22–24]. For example, the MAC of halothane in
Table 2 Biochemical markers before surgery
Group N Group A Group B P-value
TBIL (μmol/l) 9.8 (5.7,24.2) 16.85 (12.6,26.6) 42.9 (18.7,620.3)a,b <0.001
DBIL (μmol/l) 3.05 (2.1,7.9) 7.25 (5.2,9.9) 15.85 (7.9,453.9)a, b <0.001
IBIL (μmol/l) 6.65 (3.5,16.3) 10.50 (6.8,16.7) 20.1 (6.4,166.4)a 0.003
ALT (IU/l) 21.5 (16,56) 50.0 (22,156) 25.5 (10,80)a 0.016
AST (IU/l) 24.5 (19,37) 41.5 (23,142) 37.5 (10,119)a 0.014
ALB (g/l) 41.83 ± 3.83 39.13 ± 2.8 29.63 ± 4.12a, b <0.001
LDH (IU/l) 144.5 (105,247) 162.5 (56,312) 148 (105,197) 0.451
BUN (μmol/l) 6.07 (4.04,67) 5. 1 (3.59,6.72) 4.0 (3.22,11.38) 0.192
SCr (μmol/l) 91.8 (57.8,101.9) 79 (66.2,96.1) 75.05 (57,138) 0.81
Ammonia (μmol/l) 35.5 ± 20.42 49.6 ± 26.81 57.0 ± 25.99 0.158
PT (s) 10.7 (10.4,12) 12.65 (11.3,14.5) 17.4 (13.7,23.4)a, b <0.001
APTT (s) 27.45 (22.1,32.5) 30.05 (25.9,36.1) 41.45 (2.07,59)a 0.001
FIB (g/l) 2.83 (1.71,4.25) 2.78 (1.78,6.16) 1.22 (0.63,3.64)a 0.015
Data with normal distribution were presented as the means and SDs. Data without normal distribution were presented as medians with maximum and minimum.
The P-values were derived from ANOVA or Wilcoxon’s signed rank test. Bonferroni or Dunnett T3 tests were used for post hoc paired comparisons
Abbreviations: TBIL total bilirubin, DBIL direct bilirbubin, IBIL indirect blilirubin, ALT alanine aminotransferase, AST aspartame aminotransferase, ALB albumin, LDH
lactate dehydrogenase, BUN urea nitrogen, SCr serum creatinine, PT prothrombin time, APTT activated partial thromboplastin time, FIB fibrinogen
aGroup B vs. Group N, P < 0.05
bGroup B vs. Group A, P < 0.05
Table 3 Blood gas analysis before surgery
Group N Group A Group B P-value
pH 7.44 (7.36,7.49) 7.42 (7.36,7.5) 7.39 (6.97,7.53) 0.459
PaO2 (mmHg) 193.5 (156,317) 198.7 (158,251) 194.2 (112,271) 0.898
PaCO2 (mmHg) 33.81 ± 3.07 34.97 ± 8.17 37.01 ± 3.63 0.426
BE (mmol/l) −1.07 ± 2.47 −1.66 ± 2.81 −1.83 ± 9.14 0.952
HCO3
− (mmol/l) 22.49 ± 1.67 22.94 ± 2.9 22.45 ± 6.55 0.96
K+ (μmol/l) 3.37 ± 0.5 3.43 ± 0.32 3.63 ± 0.55 0.412
Na+ (μmol/l) 141.6 ± 2.72 141.26 ± 2.86 137.9 ± 3.6a 0.022
Ca2+ (μmol/l) 1.07 ± 0.07 1.08 ± 0.38 1.11 ± 0.06 0.233
Hb (g/l) 110.1 ± 39.71 100.7 ± 41.73 95.9 ± 34.72 0.408
Hct (%) 37.1 ± 6.52 33.3 ± 8.35 29 ± 10.71 0.134
aGroup B vs. Group N, P < 0.05
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children with congenital cerebral palsy or severe mental
retardation was lower than that in normal children [6].
The most widely recognized relationship between the
liver and the brain is exemplified by hepatic encephalop-
athy (HE), which is broadly divided into overt HE and
MEH, which is a subclinical HE without clinically overt
symptoms. However, MEH has been associated with in-
creased mortality, the risk of hospitalization, and in-
creased caregiver burden [25]. MHE can be diagnosed
using hypersensitive neuropsychological tests including
NCT-A and DST [26]. In this study, there were 40 and
70 % patients with MHE in Group A and Group B re-
spectively, which is consistent with the previously re-
ported prevalence of MHE in cirrhosis [27, 28]. The
MACelectric was lower in cirrhotic patients with MHE
compared those without it.
Previously studies have demonstrated that BIS is a use-
ful tool not only in monitoring the depth of anesthesia
[12, 13] but also in diagnosing MHE, HE and grading
HE [29, 30]. Consistent with these observations, our re-
sults further showed that BIS values in cirrhotic patients
with a Child-Pugh score over 6 were significantly lower
than those patients with a healthy liver (Table 4) even
before the initiation of anesthesia. It may be considered
as a predictor of reduced MAC in response to electric
stimulation in cirrhotic patients. Furthermore, cirrhotic
patients with MHE have lower BIS values than those cir-
rhotic patients without MHE. These findings suggested
that changes in the brain were the most important reason
for the decreased requirement of sevoflurane in cirrhotic
patients and that BIS values may be a useful quantitative
index for recognizing patients with liver dysfunction who
may need reduced amount of anesthetic.
Changes of plasma compositions in patients with liver
dysfunction can be complex. Here we observed changes in
liver enzymes, albumin, bilirubin and coagulation and
found a significant increase in ALT and AST in Groups A
and B patients, which indicates hepatocyte damages in
these patients. Approximately 3 % of sevoflurane absorbed
by the body is biotransformed in the liver, through cyto-
chrome P4502E1 [31]. Sevoflurane biotransformation de-
creases when hepatocytes are damaged because the
concentration of cytochrome P450 enzymes is reduced in
patients and animals with cirrhosis [32, 33]. ALT was
negatively correlated with MACelectric, which may sug-
gested that the requirement of sevoflurane is associated
Table 4 Neuropsychological test results and BIS value before
surgery
Group N Group A Group B P-value
NCT-A (s) 39.86 ± 10.0 62.29 ± 26.9 73.64 ± 32.1a 0.017
DST 11.55 (9.8,17.1) 10.25 (6.1,15.1) 8.5 (5.1,12.2)a 0.015
BIS 97 (97,99) 97 (94,97) 94 (87,97)a <0.001
MHE 0 4 7
NCT-A: The Number Connection Test A (Range of normal values: 10–66 s). DST:
Digit Symbol Test, the scores were obtained in 90 s according to Wechsler
Intelligence Scale for Adult-Chinese Revised (WAIS-RC). BIS: the bispectral
index. MHE: minimal hepatic encephalopathy, which was diagnosed if one or
both the two neuropsychological tests were abnormal
aGroup B vs. Group N, P < 0.05
Table 5 BIS value and vital signs during the study
Group N Group A Group B P-value
Before anesthesia
HR (beat/min) 76 (63,92) 83.5 (71,122) 82.5 (65,118) 0.15
SpO2 (%) 98.3 ± 1.06 97.7 ± 1.25 97.3 ± 1.83 0.3
MAP (mmHg) 82.7 ± 14.22 87.2 ± 32.05 78.9 ± 9.04 0.104
BIS 97 (97,99) 97 (94,97) 94 (87,97)a <0.001
Time of MACelectric1
HR (beat/min) 63.6 ± 7.20 76.2 ± 7.24a 71.4 ± 11.21 0.012
SpO2 (%) 100 (99,100) 100 (99,100) 100 (99,100) 0.631
MAP (mmHg) 65 (54,85) 75 (61,89) 64 (60,79)a 0.028
BIS 46.4 ± 6.69 49.1 ± 9.36 46.4 ± 6.59 0.665
Time of MACelectric2
HR (beat/min) 65.9 ± 7.05 80.7 ± 7.10a 73.7 ± 11.26 0.003
SpO2 (%) 100 (99,100) 100 (99,100) 100 (99,100) 0.631
MAP (mmHg) 67 (57,90) 85 (77,103)a 65.5 (62,84)b 0.001
BIS 52.3 ± 7.32 56.1 ± 9.13 51.2 ± 11.59 0.519
Time of MACelectric 1: The time when the lowest end-tidal concentration of
sevoflurane that prevented purposeful movement was determined
Time of MACelectric2: The time when the highest end-tidal concentration of
sevoflurane that did not prevent purposeful movement was determined
Abbreviations: HR heart rate, SpO2 pulse oximetry, MAP mean arterial pressure,
BIS bispectral index
aCompared with Group N, P < 0.05
bCompared with Group A, P < 0.05
Fig. 1 MACelectric of three groups. Reduced MACelectric in patients
with liver dysfunction. The MACelectric of each patient was calculated
as the value halfway between the end-tidal concentrations of sevo-
flurane that prevented or allowed purposeful movement in response
to the electrical stimulation (80 mA 50 Hz for 15 s). Group MACelectric
values are expressed as median ± maximum and minimum. The
MACelectric values in Groups B and A were significantly lower
than that of Group N patients with normal liver function parameters
(** p < 0.001 and * p = 0.042)
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with hepatocyte function. However, the correlation
coefficient was very minuscule (MACelectric = −0.003
ALT +0.053 BIS) and the negative association between
ALT and MACelectric cannot be interpreted as clinic-
ally relevant.
We used electrical stimulation to determine the sevo-
flurane MAC as this method has been used previously in
humans [21, 34–37]. It has been shown that electrical
stimulation is well correlated with the standard noxious
incisional stimulus [38]. The electric stimulation of
80 mA at 50Hzused in this study was a supramaximal
stimulus with reliable and predictable motor responses.
It is noninvasive, repeatable, and requires smaller sample
sizes than the classic method. MACelectric is correlated to
and less than that determined by the skin incision
method [21, 34, 35]. Our data are in normal patients
(1.51 % vs. 1.71 %) are consistent with this conclusion
and demonstrate that the intensity of the electric stimu-
lus is less than that of the skin incision.
It is important to recognize that although our primary
endpoint result showed a significant effect, the sample
size is relatively small. Further clinical trials are required
to define the relationship between BIS, the level of liver
injury, and the MAC of volatile anesthetics. Investiga-
tions concerning the mechanism in animal models are
also needed.
Conclusion
In conclusion, MACelectric of sevoflurane in cirrhotic pa-
tients was significantly lower than that of patients with
normal liver function. The severity of liver dysfunction
basing on Child- Pugh grade had no effect on the
MACelectric of sevoflurane in cirrhotic patients. ALT
and BIS were the risk factors associated the decrease
of MACelectric. MACelectric could be used by clinicians
to guide the best anesthetic practice in this population
and beyond. As the results showed, BIS should be recom-
mended to be a routine in monitoring the depth of
anesthesia in the patients with liver dysfunction. Further-
more, the BIS values measured before anesthesia could
provide a clue of exiting of MHE, which should be given
more attention in the anesthetic practice.
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